Frequently Asked Questions
Below is a list of frequently asked questions.
Alnylam was founded in 2002 by Phillip Sharp, PhD, and Noble Laureate; Paul Schimmel, PhD; David Bartel, PhD; Thomas Tuschl, PhD; and Phillip Zamore, PhD.
Alnylam was incorporated in June 2002 in the state of Delaware.
Alnylam started trading publicly in May 2004.
Our corporate headquarters and research laboratories are located in Cambridge, MA, with our large-scale manufacturing facilities located in Cambridge, MA, and Norton, MA. The European business offices are located in Maidenhead, UK, and Zug, Switzerland, with satellite offices in Munich, Germany; Amsterdam, Netherlands; Vienna, Austria; Paris, France; Milan, Italy; Madrid, Spain; and Stockholm, Sweden. Other global offices include Toyko, Japan; Sao Paulo, Brazil; and Mississauga, Ontario, Canada.
Alnylam has over 1,300 full-time employees worldwide as of December 2019.
Our common stock is listed on the NASDAQ Stock Market under the symbol ALNY.
You can purchase stock in our company through a registered brokerage or stock purchase service provider of your choice.
Unfortunately, you cannot purchase stock directly from Alnylam.
You will need to contact the broker from whom you purchased your shares.
Alnylam has never paid a cash dividend, nor has plans to pay a cash dividend in the foreseeable future.
Alnylam reports quarterly financial results roughly 4 to 6 weeks after the final day of each quarter.
Our annual stockholders’ meeting is held virtually and is coordinated by Broadridge Financial Solutions. The meeting is held annually, within the first half of each year.
Instructions are mailed to all shareholders.
Our independent auditors are PricewaterhouseCoopers LLP in Boston, Massachusetts.